Zai Lab (HKG:9688) reported $51 million in net loss for the first quarter of 2026, widening from a loss of $48.4 million a year earlier, according to a Thursday filing with the Hong Kong bourse.
The biopharmaceutical company's shares fell over 6% in morning trade Friday.
Loss per share was $0.05, compared with $0.04 in the prior year period.
Revenue fell 6% year on year to $99.6 million, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.